GBA Presents: House of Gummy-!

stonedinvestor said:
There was a Supreme Court Ruling about the ability of a president to do anything and not get in trouble if it's an official act. This is a very dangerous president/ Biden should now attack the supreme court and investigate their gay side and and expose al of their white supremacy undertows; he should attack them legally and throw their reputations into the dust bins of history. Charge them and kangaroo court them... Why? because he can.
More...
Did you "SCOOP" this SCOTUS ruling today too? :rolleyes:
 
stonedinvestor said:
VAN THERE ARE SOME DAYS WHEN I JUST DON'T LET YOU GET AWAY WITH YOUR JUNK.
TODAY IS ONE OF THOSE DAYS. YOU SAID YOU MADE SOME ECONOMIC POINTS REGARDING TRUMP AND AND I DON'T SEE THEM.. WHERE ARE THEY? TRIED AND TROPE SAYINGS LIKE "THE MARKET DOESN'T REACT WELL TO UNCERTAINTY" IS WHY WE DON'T WATCH THE TALKING HEADS ON TV!!! :D
More...
Markets don't like uncertainty. It's a fact. That's why the axiom exists. An assumed Trump win carries a certain degree of uncertainty regarding how far his enemies will go to destroy anything he tries to do.

You yourself just wrote what your "source" told you. "Violence will ensue." That's exactly one of the reasons I wrote what I wrote.

You're trying to draw me into a political argument, and I'm not going there. You debate like a child. I told you what's going to happen near term market-wise if the odds of a Trump win continue to increase. If Michelle decides to run, or another strong Dem emerges, then we'll reassess.
 
CAVA up 100%<----- :thumbsup:Did we nail that IPO or what! Nobody was talking IPO's at the time...

Tyra Biosciences 'rapidly becoming' top second half pick at Opco » 12:14 TYRA


Company Profile
TYRA

Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.

TYRA Tyra Biosciences, Inc.

$16.98
 
You must log in or register to reply here.
Back
Top